Gadobutrol in the central nervous system at three doses: Results from a phase II, randomized, multicenter trial

Josy Breuer, Juan Gutierrez, Richard E Latchaw, Robert Lehr, A. Gregory Sorensen

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose To investigate the efficacy and safety of three doses of gadobutrol and determine the minimum effective dose for contrast-enhanced MRI of the central nervous system (CNS). Materials and Methods This was a Phase II, multicenter, double-blind, parallel-group controlled study in subjects referred for contrast-enhanced MRI of the CNS. Subjects were randomized to receive gadobutrol 0.03, 0.1, or 0.3 mmol/kg body weight, and underwent unenhanced, gadobutrol-enhanced, and comparator-enhanced MRI scans. Three blinded readers assessed the images. Primary efficacy variables were number of lesions detected, border delineation, contrast enhancement, and internal morphology. Results Of the 229 randomized subjects, 173 were evaluated for efficacy. Clinically meaningful improvements in lesion border delineation, contrast enhancement, and internal morphology were observed for 0.1 mmol/kg gadobutrol. Pair-wise comparisons of a composite score of the four primary variables showed the 0.1 mmol/kg dose to be statistically superior to the 0.03 mmol/kg dose (P = 0.003). The 0.3 mmol/kg dose showed no statistically significant difference with the 0.1 mmol/kg dose. Twenty-two (9.8%) subjects reported at least one treatment-emergent adverse event (TEAE). No TEAE was reported at an incidence >3.5%. Conclusion The 0.1 mmol/kg dose of gadobutrol was effective and well tolerated for contrast-enhanced MRI of the CNS.

Original languageEnglish (US)
Pages (from-to)410-418
Number of pages9
JournalJournal of Magnetic Resonance Imaging
Volume39
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Multicenter Studies
Central Nervous System
Body Weight
Magnetic Resonance Imaging
gadobutrol
Safety
Incidence

Keywords

  • central nervous system
  • contrast-enhanced magnetic resonance imaging
  • gadobutrol

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Gadobutrol in the central nervous system at three doses : Results from a phase II, randomized, multicenter trial. / Breuer, Josy; Gutierrez, Juan; Latchaw, Richard E; Lehr, Robert; Sorensen, A. Gregory.

In: Journal of Magnetic Resonance Imaging, Vol. 39, No. 2, 02.2014, p. 410-418.

Research output: Contribution to journalArticle

Breuer, Josy ; Gutierrez, Juan ; Latchaw, Richard E ; Lehr, Robert ; Sorensen, A. Gregory. / Gadobutrol in the central nervous system at three doses : Results from a phase II, randomized, multicenter trial. In: Journal of Magnetic Resonance Imaging. 2014 ; Vol. 39, No. 2. pp. 410-418.
@article{cf68198f0f5a446b9889dcf35fa9224b,
title = "Gadobutrol in the central nervous system at three doses: Results from a phase II, randomized, multicenter trial",
abstract = "Purpose To investigate the efficacy and safety of three doses of gadobutrol and determine the minimum effective dose for contrast-enhanced MRI of the central nervous system (CNS). Materials and Methods This was a Phase II, multicenter, double-blind, parallel-group controlled study in subjects referred for contrast-enhanced MRI of the CNS. Subjects were randomized to receive gadobutrol 0.03, 0.1, or 0.3 mmol/kg body weight, and underwent unenhanced, gadobutrol-enhanced, and comparator-enhanced MRI scans. Three blinded readers assessed the images. Primary efficacy variables were number of lesions detected, border delineation, contrast enhancement, and internal morphology. Results Of the 229 randomized subjects, 173 were evaluated for efficacy. Clinically meaningful improvements in lesion border delineation, contrast enhancement, and internal morphology were observed for 0.1 mmol/kg gadobutrol. Pair-wise comparisons of a composite score of the four primary variables showed the 0.1 mmol/kg dose to be statistically superior to the 0.03 mmol/kg dose (P = 0.003). The 0.3 mmol/kg dose showed no statistically significant difference with the 0.1 mmol/kg dose. Twenty-two (9.8{\%}) subjects reported at least one treatment-emergent adverse event (TEAE). No TEAE was reported at an incidence >3.5{\%}. Conclusion The 0.1 mmol/kg dose of gadobutrol was effective and well tolerated for contrast-enhanced MRI of the CNS.",
keywords = "central nervous system, contrast-enhanced magnetic resonance imaging, gadobutrol",
author = "Josy Breuer and Juan Gutierrez and Latchaw, {Richard E} and Robert Lehr and Sorensen, {A. Gregory}",
year = "2014",
month = "2",
doi = "10.1002/jmri.24180",
language = "English (US)",
volume = "39",
pages = "410--418",
journal = "Journal of Magnetic Resonance Imaging",
issn = "1053-1807",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Gadobutrol in the central nervous system at three doses

T2 - Results from a phase II, randomized, multicenter trial

AU - Breuer, Josy

AU - Gutierrez, Juan

AU - Latchaw, Richard E

AU - Lehr, Robert

AU - Sorensen, A. Gregory

PY - 2014/2

Y1 - 2014/2

N2 - Purpose To investigate the efficacy and safety of three doses of gadobutrol and determine the minimum effective dose for contrast-enhanced MRI of the central nervous system (CNS). Materials and Methods This was a Phase II, multicenter, double-blind, parallel-group controlled study in subjects referred for contrast-enhanced MRI of the CNS. Subjects were randomized to receive gadobutrol 0.03, 0.1, or 0.3 mmol/kg body weight, and underwent unenhanced, gadobutrol-enhanced, and comparator-enhanced MRI scans. Three blinded readers assessed the images. Primary efficacy variables were number of lesions detected, border delineation, contrast enhancement, and internal morphology. Results Of the 229 randomized subjects, 173 were evaluated for efficacy. Clinically meaningful improvements in lesion border delineation, contrast enhancement, and internal morphology were observed for 0.1 mmol/kg gadobutrol. Pair-wise comparisons of a composite score of the four primary variables showed the 0.1 mmol/kg dose to be statistically superior to the 0.03 mmol/kg dose (P = 0.003). The 0.3 mmol/kg dose showed no statistically significant difference with the 0.1 mmol/kg dose. Twenty-two (9.8%) subjects reported at least one treatment-emergent adverse event (TEAE). No TEAE was reported at an incidence >3.5%. Conclusion The 0.1 mmol/kg dose of gadobutrol was effective and well tolerated for contrast-enhanced MRI of the CNS.

AB - Purpose To investigate the efficacy and safety of three doses of gadobutrol and determine the minimum effective dose for contrast-enhanced MRI of the central nervous system (CNS). Materials and Methods This was a Phase II, multicenter, double-blind, parallel-group controlled study in subjects referred for contrast-enhanced MRI of the CNS. Subjects were randomized to receive gadobutrol 0.03, 0.1, or 0.3 mmol/kg body weight, and underwent unenhanced, gadobutrol-enhanced, and comparator-enhanced MRI scans. Three blinded readers assessed the images. Primary efficacy variables were number of lesions detected, border delineation, contrast enhancement, and internal morphology. Results Of the 229 randomized subjects, 173 were evaluated for efficacy. Clinically meaningful improvements in lesion border delineation, contrast enhancement, and internal morphology were observed for 0.1 mmol/kg gadobutrol. Pair-wise comparisons of a composite score of the four primary variables showed the 0.1 mmol/kg dose to be statistically superior to the 0.03 mmol/kg dose (P = 0.003). The 0.3 mmol/kg dose showed no statistically significant difference with the 0.1 mmol/kg dose. Twenty-two (9.8%) subjects reported at least one treatment-emergent adverse event (TEAE). No TEAE was reported at an incidence >3.5%. Conclusion The 0.1 mmol/kg dose of gadobutrol was effective and well tolerated for contrast-enhanced MRI of the CNS.

KW - central nervous system

KW - contrast-enhanced magnetic resonance imaging

KW - gadobutrol

UR - http://www.scopus.com/inward/record.url?scp=84892829618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892829618&partnerID=8YFLogxK

U2 - 10.1002/jmri.24180

DO - 10.1002/jmri.24180

M3 - Article

C2 - 23681501

AN - SCOPUS:84892829618

VL - 39

SP - 410

EP - 418

JO - Journal of Magnetic Resonance Imaging

JF - Journal of Magnetic Resonance Imaging

SN - 1053-1807

IS - 2

ER -